Loading...
Keywords
Last Name
Institution
 Back to Details

Connection

J. Steven Leeder to Cytochrome P-450 CYP2D6

This is a "connection" page, showing publications J. Steven Leeder has written about Cytochrome P-450 CYP2D6.

 
Connection Strength
  
 
 
9.221
  
  1. Leeder JS, Gaedigk A, Wright KJ, Staggs VS, Soden SE, Lin YS, Pearce RE. A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence. Clin Transl Sci. 2022 Oct; 15(10):2514-2527.
    View in: PubMed
    Score: 0.743
  2. Chapron BD, Dinh JC, Toren PC, Gaedigk A, Leeder JS. The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. Drug Metab Dispos. 2020 11; 48(11):1113-1120.
    View in: PubMed
    Score: 0.647
  3. Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, de Leon J, Leeder JS. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019 07; 106(1):94-102.
    View in: PubMed
    Score: 0.589
  4. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017 01; 19(1):69-76.
    View in: PubMed
    Score: 0.486
  5. Brown JT, Abdel-Rahman SM, van Haandel L, Gaedigk A, Lin YS, Leeder JS. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin Pharmacol Ther. 2016 06; 99(6):642-50.
    View in: PubMed
    Score: 0.470
  6. Gaedigk A, Riffel AK, Leeder JS. CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification: Resolution of a Complex Genotype and a Discordant Genotype Involving the CYP2D6*59 Allele. J Mol Diagn. 2015 Nov; 17(6):740-8.
    View in: PubMed
    Score: 0.458
  7. Gaedigk A, Freeman N, Hartshorne T, Riffel AK, Irwin D, Bishop JR, Stein MA, Newcorn JH, Jaime LK, Cherner M, Leeder JS. SNP genotyping using TaqMan technology: the CYP2D6*17 assay conundrum. Sci Rep. 2015 Mar 19; 5:9257.
    View in: PubMed
    Score: 0.444
  8. Leeder JS, Gaedigk A. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects. Pharmacogenomics. 2014 Jun; 15(8):1055-8.
    View in: PubMed
    Score: 0.420
  9. Gaedigk A, Leeder JS. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects. Pharmacogenomics. 2014 Mar; 15(4):407-10.
    View in: PubMed
    Score: 0.413
  10. Gaedigk A, Fuhr U, Johnson C, B?rard LA, Bradford D, Leeder JS. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics. 2010 Jan; 11(1):43-53.
    View in: PubMed
    Score: 0.309
  11. Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI. Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol. 2008 Sep; 48(9):1041-51.
    View in: PubMed
    Score: 0.282
  12. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008 Feb; 83(2):234-42.
    View in: PubMed
    Score: 0.266
  13. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006 Aug 19; 368(9536):704.
    View in: PubMed
    Score: 0.245
  14. Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos. 2006 Apr; 34(4):563-9.
    View in: PubMed
    Score: 0.235
  15. Gaedigk A, Gaedigk R, Leeder JS. CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? Biochem Biophys Res Commun. 2005 Nov 04; 336(4):1241-50.
    View in: PubMed
    Score: 0.232
  16. Gaedigk A, Bhathena A, Ndjountch? L, Pearce RE, Abdel-Rahman SM, Alander SW, Bradford LD, Rogan PK, Leeder JS. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J. 2005; 5(3):173-82.
    View in: PubMed
    Score: 0.219
  17. Gaedigk A, Ryder DL, Bradford LD, Leeder JS. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem. 2003 Jun; 49(6 Pt 1):1008-11.
    View in: PubMed
    Score: 0.196
  18. Rogan PK, Svojanovsky S, Leeder JS. Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics. 2003 Apr; 13(4):207-18.
    View in: PubMed
    Score: 0.194
  19. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002 Jul; 72(1):76-89.
    View in: PubMed
    Score: 0.184
  20. Dinh JC, Boone EC, Staggs VS, Pearce RE, Wang WY, Gaedigk R, Leeder JS, Gaedigk A. The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity. Clin Pharmacol Ther. 2022 03; 111(3):646-654.
    View in: PubMed
    Score: 0.177
  21. Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, Klein TE, Haidar CE, Van Driest SL, Ruano G, Sangkuhl K, Cavallari LH, M?ller DJ, Prows CA, Nagy M, Somogyi AA, Skaar TC. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021 10; 110(4):888-896.
    View in: PubMed
    Score: 0.167
  22. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999 Dec; 9(6):669-82.
    View in: PubMed
    Score: 0.154
  23. Bradford LD, Gaedigk A, Leeder JS. High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data. Psychopharmacol Bull. 1998; 34(4):797-804.
    View in: PubMed
    Score: 0.135
  24. Gaedigk A, Ndjountch? L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, Brousseau DC, McCarver DG, Johnson JA, Alander SW, Wayne Riggs K, Steven Leeder J. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther. 2007 Feb; 81(2):242-51.
    View in: PubMed
    Score: 0.126
  25. Hicks JK, Bishop JR, Sangkuhl K, M?ller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 Aug; 98(2):127-34.
    View in: PubMed
    Score: 0.113
  26. Tay-Sontheimer J, Shireman LM, Beyer RP, Senn T, Witten D, Pearce RE, Gaedigk A, Gana Fomban CL, Lutz JD, Isoherranen N, Thummel KE, Fiehn O, Leeder JS, Lin YS. Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics. 2014 Dec; 15(16):1947-62.
    View in: PubMed
    Score: 0.109
  27. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014 Apr; 95(4):376-82.
    View in: PubMed
    Score: 0.103
  28. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet. 2014 Jan 01; 23(1):268-78.
    View in: PubMed
    Score: 0.100
  29. Gaedigk A, Twist GP, Leeder JS. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics. 2012 Jan; 13(1):91-111.
    View in: PubMed
    Score: 0.088
  30. Madadi P, Ciszkowski C, Gaedigk A, Leeder JS, Teitelbaum R, Chitayat D, Koren G. Genetic transmission of cytochrome P450 2D6 (CYP2D6) ultrarapid metabolism: implications for breastfeeding women taking codeine. Curr Drug Saf. 2011 Feb 01; 6(1):36-9.
    View in: PubMed
    Score: 0.083
  31. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009 Jan; 85(1):31-5.
    View in: PubMed
    Score: 0.070
  32. Gaedigk A, Eklund JD, Pearce RE, Leeder JS, Alander SW, Phillips MS, Bradford LD, Kennedy MJ. Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype. Clin Pharmacol Ther. 2007 Jun; 81(6):817-20.
    View in: PubMed
    Score: 0.064
  33. Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther. 2007 Apr; 81(4):510-6.
    View in: PubMed
    Score: 0.063
  34. Gaedigk A, Ndjountch? L, Leeder JS, Bradford LD. Limited association of the 2988g > a single nucleotide polymorphism with CYP2D641 in black subjects. Clin Pharmacol Ther. 2005 Mar; 77(3):228-30; author reply 230-1.
    View in: PubMed
    Score: 0.055
  35. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. 2004 Dec; 76(6):536-44.
    View in: PubMed
    Score: 0.054
  36. Kennedy MJ, Abdel-Rahman SM, Kashuba AD, Leeder JS. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol. 2004 Jul; 44(7):708-14.
    View in: PubMed
    Score: 0.053
  37. Gaedigk A, Ndjountch? L, Gaedigk R, Leeder JS, Bradford LD. Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects. Clin Pharmacol Ther. 2003 Jun; 73(6):575-6.
    View in: PubMed
    Score: 0.049
  38. Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Rua?o G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023 07; 114(1):51-68.
    View in: PubMed
    Score: 0.049
  39. Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, Gaedigk A. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab Dispos. 2002 May; 30(5):595-601.
    View in: PubMed
    Score: 0.045
  40. Abdel-Rahman SM, Leeder JS, Wilson JT, Gaedigk A, Gotschall RR, Medve R, Liao S, Spielberg SP, Kearns GL. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol. 2002 Jan; 42(1):24-9.
    View in: PubMed
    Score: 0.044
  41. Leeder JS. Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am. 2001 Jun; 48(3):765-81.
    View in: PubMed
    Score: 0.043
  42. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther. 2000 Oct; 68(4):375-83.
    View in: PubMed
    Score: 0.041
  43. Streetman DS, Ellis RE, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clin Pharmacol Ther. 1999 Nov; 66(5):535-41.
    View in: PubMed
    Score: 0.038
  44. Hicks JK, Bishop JR, Gammal RS, Sangkuhl K, Bousman CA, Leeder JS, Llerena A, Mueller DJ, Ramsey LB, Scott SA, Skaar TC, Caudle KE, Klein TE, Gaedigk A. A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clin Pharmacol Ther. 2020 01; 107(1):50-52.
    View in: PubMed
    Score: 0.038
  45. Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos. 1999 Jul; 27(7):770-5.
    View in: PubMed
    Score: 0.037
  46. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, Gaedigk A, Bertino JS. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics. 1998 Oct; 8(5):403-10.
    View in: PubMed
    Score: 0.035
  47. Madadi P, Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder JS, Teitelbaum R, Karaskov T, Aleksa K. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician. 2007 Jan; 53(1):33-5.
    View in: PubMed
    Score: 0.016
  48. Findling RL, Nucci G, Piergies AA, Gomeni R, Bartolic EI, Fong R, Carpenter DJ, Leeder JS, Gaedigk A, Danoff TM. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology. 2006 Jun; 31(6):1274-85.
    View in: PubMed
    Score: 0.015
  49. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 2003 Nov; 74(5):437-47.
    View in: PubMed
    Score: 0.013
  50. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Gaedigk A, Bertino JS. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics. 1999 Aug; 9(4):453-62.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.